Good design can help transform health care, in part because it involves drawing on a wide range of perspectives and experiences. This month, we talked with a health care designer, a patient advocate, and a physician to learn how “design thinking” can be successfully incorporated into health care systems and applications.
The stigma associated with HIV has diminished with its spread among the heterosexual population and the development of effective treatments. This normalization may justify assuming a more traditional public health perspective about mandatory prenatal screening.
Dr. Jones has a duty to determine how the test results were lost and why, disclose this information to his patient, Mrs. Taylor, and see that she is not held responsible for the costs of rerunning the test.
We must not pit immigration policy and health care needs against one another. We need better policy on immigration, and that policy should confront immigration at the workplace and at the border—not in the hospital emergency room.
Gerald M. Oppenheimer, PhD, MPH and Ronald Bayer, PhD
The alarm generated by the AIDS epidemic left civil liberties proponents fearful that traditional public health responses might be imposed on newly susceptible or infected populations.
With heterosexual transmission the chief cause of global HIV spread, those without the power to select sexual partners, choose the timing of sexual encounters, or insist on safer sex practices are unable to protect themselves from infection.
Cynthia E. Schairer, PhD, Caryn Kseniya Rubanovich, MS, and Cinnamon S. Bloss, PhD
Questions about data privacy need to be addressed when research institutions negotiate with companies developing mobile health applications. Commercial terms of use and data sharing notifications should be reviewed before use in human subject research settings.
AMA J Ethics. 2018;20(9):E864-872. doi:
10.1001/amajethics.2018.864.
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”